New technique uses ultrasound to kill prostate cancer with no surgery and 80% success rate
After treatment, 65 per cent of men in study had no signs of cancer after one year
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Doctors have used ultrasound to successfully treat prostate cancer in a new study promising a new alternative to surgery.
Prostate is the second most deadly type of cancer in men, with lung cancer the only variant to claim more lives.
Treatment is challenging because surgery and radiation can leave men incontinent or impotent.
However, a pioneering new technique avoids the risks by using a rod-shaped device inserted into the urethra while guided by magnetic resonance to administer precise bursts of ultrasound.
The sound waves heat and destroy the tumour, leaving surrounding areas unharmed.
The new study was presented at the annual meeting of the Radiological Society of North America and involved 115 men with localised prostate cancer.
After treatment with ultrasound, clinically significant cancer was eliminated in 80 per cent of the group, with 65 per cent having no signs of cancer after one year.
Most of the men also saw reduced blood-antigen markers for prostate cancer, and overall no bowel complications were reported.
Study co-author Steven Raman, professor of radiology and urology at the University of California at Los Angeles, said: “It’s an outpatient procedure with minimal recovery time.
“We saw very good results in the patients, with a dramatic reduction of over 90 per cent in prostate volume and low rates of impotence with almost no incontinence.”
The process, called Tulsa-Pro, has been approved for clinical use in Europe.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments